Prime Medicine, Inc. (PRME) Price & Analysis

Compare

744 Followers

PRME Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.11 - $5.17

Previous CloseN/A

Volume144.88K

Average Volume (3M)4.62M

Market Cap

$577.36M

Enterprise Value$337.08M

Total Cash (Recent Filing)$98.34M

Total Debt (Recent Filing)$119.74M

Price to Earnings (P/E)―

Beta3.18

Next Earnings

Oct 31, 2025

EPS Estimate

-0.25

Last Dividend Ex-Date

Sep 10, 2019

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding178,196,010

10 Day Avg. Volume3,992,766

30 Day Avg. Volume4,616,492

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.58

Enterprise Value/Revenue67.95

Enterprise Value/Gross Profit108.84

Enterprise Value/Ebitda-1.69

Forecast

1Y Price Target

$6.67

Price Target Upside107.14% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Financial PerformanceThe net proceeds from the offering were approximately $138.2M, which meaningfully strengthened the company's balance sheet and removed its near-term financial overhang.

FundingThe Cystic Fibrosis Foundation committed up to $24 million in additional funding to accelerate the development of prime editors for Cystic Fibrosis.

Gene Editing TechnologyPRME is believed to own the overall best gene editing technology, particularly in light of VERV's proposed acquisition.

Bears Say

Clinical DataPrime is expected to remain a preclinical-stage company for the near term, with no clinical data expected until 2027.

Market RatingNeutral rating on PRME is maintained without a price target due to the lack of near-term meaningful catalysts and legal uncertainty.

Revenue And EarningsPrime reported collaboration revenue of $1.1M and a net loss of $0.41 per share, compared to the consensus estimates of $4.2M and a net loss of $0.35 per share.

Prime Medicine, Inc. News

Prime Medicine reports Q2 EPS (41c), consensus (34c)

Reports Q2 revenue $1.115M, consensus $3M. “Recent months have been transformative for Prime Medicine (PRME). We announced initial...

16d ago

PRME

Cathie Wood Buys $69M Worth of Figma Stock on Blockbuster IPO Debut

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) snapped up 60,000 shares of newly-listed tech company Figma ($FIG) on July 31....

21d ago

AMD

Prime Medicine 38M share Spot Secondary priced at $3.30

TD Cowen and BMO Capital are acting as joint book running managers for the offering. The deal priced...

23d ago

PRME

Prime Medicine announces common stock offering, no amount given

Prime Medicine (PRME) announced that it has commenced an underwritten public offering of shares of its common stock....

23d ago

PRME

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Blaize Holdings Inc (BZAI)...

26d ago

SLI

AAPL

Prime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Prime Medicine, Inc., with...

14d ago

PRME

Prime Medicine Reports Q2 2025 Results and Strategic Updates

Prime Medicine, Inc. ( ($PRME) ) has released its Q2 earnings. Here is a breakdown of the information...

15d ago

PRME

Prime Medicine Holds Special Stockholder Meeting

The latest announcement is out from Prime Medicine, Inc. ( ($PRME) ). On August 1, 2025, Prime Medicine,...

17d ago

PRME

Prime Medicine Announces $120.2M Public Stock Offering

Prime Medicine, Inc. ( ($PRME) ) just unveiled an update. On July 30, 2025, Prime Medicine, Inc. entered...

22d ago

PRME

Prime Medicine Halts Sales Agreement Prospectus

Prime Medicine, Inc. ( ($PRME) ) has provided an update. On July 30, 2025, Prime Medicine, Inc. terminated...

23d ago

PRME

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Ouster Inc (OUST) 1.87%...

1M ago

QID

ABSI

Prime Medicine, Inc.: Buy Rating Affirmed on Innovative Gene Editing Technology and Strategic Advancements

BMO Capital analyst Kostas Biliouris maintained a Buy rating on Prime Medicine, Inc. yesterday and set a price...

1M ago

PRME

Prime Medicine announces additional funding of up to $24M from CF Foundation

Prime Medicine (PRME) announced that the Cystic Fibrosis Foundation has agreed to provide the Company with up to...

1M ago

PRME

Prime Medicine Announces CSO Resignation and Transition

An update from Prime Medicine, Inc. ( ($PRME) ) is now available. On July 14, 2025, Prime Medicine,...

1M ago

PRME

PRME FAQ

What was Prime Medicine, Inc.’s price range in the past 12 months?

Prime Medicine, Inc. lowest stock price was $1.11 and its highest was $5.17 in the past 12 months.

What is Prime Medicine, Inc.’s market cap?

Prime Medicine, Inc.’s market cap is $577.36M.

When is Prime Medicine, Inc.’s upcoming earnings report date?

Prime Medicine, Inc.’s upcoming earnings report date is Oct 31, 2025 which is in 69 days.

How were Prime Medicine, Inc.’s earnings last quarter?

Prime Medicine, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.351 by -$0.059.

Is Prime Medicine, Inc. overvalued?

According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Prime Medicine, Inc. pay dividends?

Prime Medicine, Inc. pays a Quarterly dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Prime Medicine, Inc. dividends here

What is Prime Medicine, Inc.’s EPS estimate?

Prime Medicine, Inc.’s EPS estimate is -0.25.

How many shares outstanding does Prime Medicine, Inc. have?

Prime Medicine, Inc. has 178,196,010 shares outstanding.

What happened to Prime Medicine, Inc.’s price movement after its last earnings report?

Prime Medicine, Inc. reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.351. Following the earnings report the stock price went down -9.582%.

Which hedge fund is a major shareholder of Prime Medicine, Inc.?

Currently, no hedge funds are holding shares in PRME

Prime Medicine, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-154.81%

Trailing 12-Months

Asset Growth

7.43%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Prime Medicine, Inc.

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Prime Medicine, Inc. (PRME) Earnings & Revenues

Historic Earnings Reports

PRME Stock 12 Month Forecast

Average Price Target

$6.67

▲(107.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.04,4.498461538461538,4.956923076923077,5.415384615384616,5.873846153846154,6.332307692307692,6.7907692307692304,7.24923076923077,7.707692307692308,8.166153846153847,8.624615384615385,9.083076923076923,9.541538461538462,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.04,4.242307692307692,4.444615384615385,4.646923076923077,4.849230769230769,5.0515384615384615,5.253846153846154,5.456153846153846,5.658461538461538,5.860769230769231,6.063076923076923,6.265384615384615,6.467692307692308,{"y":6.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.04,4.036923076923077,4.033846153846154,4.030769230769231,4.027692307692308,4.024615384615385,4.021538461538461,4.018461538461539,4.015384615384615,4.012307692307692,4.009230769230769,4.006153846153846,4.003076923076923,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.19,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.28,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.03,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >